Even though the main patent expires in 2018 in the US and 2013 in the UK, the patents surrounding the clinical work in specific areas, such as HIV and pain management, will still be worth a bucket load of money if a viable therapeutic comes out of it. If only one of these projects succeeds, the company will be worth xtimes more than 1.5 cents.
It's true that shareholders won't get value from the full potential of the technology because of the 2018 expiry but BLT will still be worth a bucket full because of the foresight of the current management.
BLT Price at posting:
37.5¢ Sentiment: LT Buy Disclosure: Held
